These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37971125)

  • 21. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D; Goode KM; Cleland JG; Clark AL
    Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.
    Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W
    Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials.
    Bryan Richard S; Huang B; Liu G; Yang Y; Luo S
    Clin Cardiol; 2021 Apr; 44(4):463-471. PubMed ID: 33638556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a.
    Shao S; Zhang Y; Gong M; Yang Q; Yuan M; Yuan M; Suo Y; Wang X; Li Y; Bao Q; Li G
    Oxid Med Cell Longev; 2021; 2021():1257283. PubMed ID: 34630844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced inferior wall longitudinal strain is associated with malignant arrhythmias in non-ischemic heart failure.
    Winsløw U; Elming MB; Thune JJ; Haarbo J; Thornvig Philbert B; Svendsen JH; Pehrson S; Jøns C; Bundgaard H; Køber L; Risum N
    Pacing Clin Electrophysiol; 2023 Jul; 46(7):721-728. PubMed ID: 37120825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebral haemodynamics during arrhythmia in health, ischaemic heart disease and heart failure with reduced ejection fraction, and in a preclinical swine model.
    Marshall RA; Luchkanych AMS; Morton JS; Boyes NG; Zhai A; Marciniuk DD; Mei Y; Allison EY; Shoemaker JK; Al-Khazraji BK; Allen MD; Tomczak CR; Olver TD
    J Physiol; 2022 May; 600(10):2311-2325. PubMed ID: 35389526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initiation of ivabradine in cardiogenic shock.
    Chiu MH; Howlett JG; Sharma NC
    ESC Heart Fail; 2019 Oct; 6(5):1088-1091. PubMed ID: 31332966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inadequate, inappropriate sinus-node tachycardia: an old cardiac arrhythmia in a new perspective (II.): Our experiences with the pharmacological treatment].
    Borbola J; Földesi C; Kardos A; Som Z
    Orv Hetil; 2020 Nov; 161(46):1953-1958. PubMed ID: 33190126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of remotely monitored nocturnal heart rate in heart failure patients with reduced ejection fraction.
    D'Onofrio A; Marini M; Rovaris G; Zanotto G; Calvi V; Iacopino S; Biffi M; Solimene F; Della Bella P; Caravati F; Pisanò EC; Amellone C; D'Alterio G; Pedretti S; Santobuono VE; Russo AD; Nicolis D; De Salvia A; Baroni M; Quartieri F; Manzo M; Rapacciuolo A; Saporito D; Maines M; Marras E; Bontempi L; Morani G; Giacopelli D; Gargaro A; Giammaria M
    Heart Rhythm; 2023 Feb; 20(2):233-240. PubMed ID: 37283031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction.
    Ennezat PV; Cosgrove S; Marechaux S; Bouvaist H; Le Jemtel TH; Vital Durand D
    Acta Cardiol; 2017 Dec; 72(6):664-668. PubMed ID: 28656798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline and Dynamic Risk Predictors of Appropriate Implantable Cardioverter Defibrillator Therapy.
    Wu KC; Wongvibulsin S; Tao S; Ashikaga H; Stillabower M; Dickfeld TM; Marine JE; Weiss RG; Tomaselli GF; Zeger SL
    J Am Heart Assoc; 2020 Oct; 9(20):e017002. PubMed ID: 33023350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term Effects of High-Dose Caffeine on Cardiac Arrhythmias in Patients With Heart Failure: A Randomized Clinical Trial.
    Zuchinali P; Souza GC; Pimentel M; Chemello D; Zimerman A; Giaretta V; Salamoni J; Fracasso B; Zimerman LI; Rohde LE
    JAMA Intern Med; 2016 Dec; 176(12):1752-1759. PubMed ID: 27749954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left Ventricular Dilatation Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic Function.
    Aleong RG; Mulvahill MJ; Halder I; Carlson NE; Singh M; Bloom HL; Dudley SC; Ellinor PT; Shalaby A; Weiss R; Gutmann R; Sauer WH; Narayanan K; Chugh SS; Saba S; London B
    J Am Heart Assoc; 2015 Jul; 4(8):e001566. PubMed ID: 26231842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
    Wilkoff BL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heart failure as a substrate and trigger for ventricular tachycardia.
    Alvarez CK; Cronin E; Baker WL; Kluger J
    J Interv Card Electrophysiol; 2019 Dec; 56(3):229-247. PubMed ID: 31598875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term arrhythmia-free survival in patients with severe left ventricular dysfunction and no inducible ventricular tachycardia after myocardial infarction.
    Zaman S; Narayan A; Thiagalingam A; Sivagangabalan G; Thomas S; Ross DL; Kovoor P
    Circulation; 2014 Feb; 129(8):848-54. PubMed ID: 24381209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Implications of Ivabradine in the Contemporary Era.
    Imamura T
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction.
    Sun AY; Koontz JI; Shah SH; Piccini JP; Nilsson KR; Craig D; Haynes C; Gregory SG; Hranitzky PM; Pitt GS
    Circ Cardiovasc Genet; 2011 Apr; 4(2):163-8. PubMed ID: 21498565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.